Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Construction in Progress (2021 - 2023)

Arrowhead Pharmaceuticals' Construction in Progress history spans 3 years, with the latest figure at $166.7 million for Q3 2023.

  • For Q3 2023, Construction in Progress rose 195.63% year-over-year to $166.7 million; the TTM value through Sep 2023 reached $166.7 million, up 195.63%, while the annual FY2023 figure was $166.7 million, 195.63% up from the prior year.
  • Construction in Progress reached $166.7 million in Q3 2023 per ARWR's latest filing, up from $118.3 million in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $166.7 million in Q3 2023 to a low of $345000.0 in Q3 2021.
  • Average Construction in Progress over 3 years is $65.6 million, with a median of $56.4 million recorded in 2022.
  • Peak YoY movement for Construction in Progress: soared 16240.0% in 2022, then surged 195.63% in 2023.
  • A 3-year view of Construction in Progress shows it stood at $2.2 million in 2021, then skyrocketed by 4092.15% to $90.2 million in 2022, then soared by 84.73% to $166.7 million in 2023.
  • Per Business Quant, the three most recent readings for ARWR's Construction in Progress are $166.7 million (Q3 2023), $118.3 million (Q2 2023), and $127.2 million (Q1 2023).